Artificial intelligence (AI) isn't the only industry with explosive growth potential.

A new CRISPR-based one-off procedure that lowers "bad" cholesterol has been approved to enter Phase I human trial. If ...

Nobel laureate Jennifer Doudna, PhD; Matthew Porteus, MD, PhD, and Rodolphe Barrangou, PhD—offer their views on the commercial potential and challenges of genome editing following a rollercoaster 2025 ...

CRISPR Therapeutics (NASDAQ:CRSP) is one of the stocks that should double by 2030. On January 30, Citizens maintained an Outperform rating on CRISPR Therapeutics while reducing the price target from ...

The hold followed Intellia’s voluntary pause in response to a grade 4 liver event—a case of Hy’s Law—in the ATTR-CM trial.

Researchers identified AlCas12a, a compact, versatile enzyme that improves CRISPR gene editing and enables faster molecular ...

CRISPR biosensors are transforming healthcare by detecting biomarkers at attomolar sensitivity, enabling real-time health monitoring through wearable patches and implantable sensors. They continuously ...

Last year, a ten-month-old baby in the US was the first person in the world to have their rare genetic disease effectively ...

Swiss-American biotechnology company, CRISPR Therapeutics AG (NASDAQ: CRSP), has come under renewed pressure in recent weeks, ...

In this article, we will take a look at the Top 10 CRISPR Stocks to Buy Now. Innovation is a hallmark of the biopharmaceutical sector, which is fueled by the demand for novel therapies to address ...

CRISPR Therapeutics AG (NASDAQ:CRSP) is one of the 10 Stocks Going Wild. Crispr Therapeutics rallied for a second day on Wednesday, adding 9.6 percent to close at $60.08 apiece, tracking the rally in ...

Cathie Wood aims to identify innovators and invest in them early in their stories. Wood has been regularly adding to her position in this stock, and it’s one of her top holdings. 10 stocks we like ...